H. Thomas Watkins III

Mr. Watkins was President, CEO and a Director of Human Genome Sciences (HGS) from 2004 until the company was acquired by GlaxoSmithKline in 2012. During his tenure, HGS successfully developed and brought Benlysta to market, the first new lupus drug to be introduced in over 50 years. Prior to HGS, Mr. Watkins spent more than 20 years in senior roles at Abbott and its affiliates in the U.S. and Asia. During that time, he was President of TAP Pharmaceutical Products, Inc., where he led the growth from approximately $2 billion to over $4 billion in annual revenue. Previously, Mr. Watkins was a consultant with McKinsey and began his career with Arthur Andersen. He is former Chairman of the Biotechnology Industry Organization and continues to serve on its board. He is currently Chairman of the Board of Vanda Pharmaceuticals, Inc., and on the board of Horizon Pharma plc. He also serves on the board of Visitors of the College of William & Mary and the board of the Ann and Robert H. Lurie Children’s Hospital of Chicago. Mr. Watkins received his B.B.A. in accounting from William & Mary and his M.B.A. from the University of Chicago Graduate School of Business, now the Booth School of Business.